Semaglutide vs Tirzepatide: Comparing GLP-1 Medications

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating. It signals your brain to reduce appetite, slows gastric emptying so you feel full longer, and helps regulate blood sugar. GLP-1 medications mimic this hormone at higher, more sustained levels than your body typically produces.

Semaglutide and Tirzepatide are both injectable GLP-1 medications administered once weekly. They have been FDA-approved for weight management and have shown significant results in clinical trials. But they are not identical, and the differences matter when choosing which is right for you.

How Semaglutide Works

Semaglutide is sold under brand names Wegovy (for weight loss) and Ozempic (for type 2 diabetes). It is a pure GLP-1 receptor agonist, meaning it activates only one hormone pathway.

The STEP clinical trial program studied Semaglutide extensively. In the STEP 1 trial published in the New England Journal of Medicine, participants taking 2.4mg Semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. For a 200-pound person, that is roughly 30 pounds.

Semaglutide has been available longer and has a broader body of real-world data behind it. Most providers have extensive experience dosing and managing it.

How Tirzepatide Works

Tirzepatide is sold as Zepbound (for weight loss) and Mounjaro (for type 2 diabetes). Unlike Semaglutide, Tirzepatide is a dual-action medication. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.

This dual mechanism appears to produce stronger results. In the SURMOUNT-1 trial published in the New England Journal of Medicine, participants taking the highest dose of Tirzepatide (15mg) lost an average of 22.5% of their body weight over 72 weeks. At the 10mg dose, average weight loss was 21.4%. These are the largest weight loss results seen in any GLP-1 medication trial to date.

The GIP receptor activation adds metabolic benefits beyond appetite suppression, including improved insulin sensitivity and potentially greater fat loss relative to lean mass preservation.

Side Effects: What to Expect

Both medications share similar side effects because they work on overlapping pathways. The most common are nausea, vomiting, diarrhea, and constipation. These are typically worst during the first few weeks and during dose increases, then improve as your body adjusts.

In clinical trials, gastrointestinal side effects occurred in roughly 40-50% of participants for both drugs. Most were mild to moderate. Serious side effects are rare but can include pancreatitis and gallbladder issues.

Anecdotally, some providers report that Tirzepatide causes slightly less nausea than Semaglutide at equivalent efficacy doses, but this has not been confirmed in head-to-head trials. Both medications require slow dose titration, starting low and increasing gradually over several weeks to minimize side effects.

Which One Is Right for You?

There is no universal answer. The choice depends on your medical history, weight loss goals, insurance coverage, and how your body responds.

Semaglutide may be a better fit if you want a medication with a longer track record and more real-world data, if your insurance covers Wegovy, or if you are looking for moderate, steady weight loss.

Tirzepatide may be a better fit if you want the strongest possible weight loss effect, if you have significant insulin resistance, or if you have tried Semaglutide and plateaued.

At Vivolo, our medical team evaluates your labs, health history, and goals before recommending a medication. We also pair every GLP-1 program with one-on-one nutrition coaching through the OLO Method, because medication alone does not build the habits you need to maintain your results after you stop the drug.

Why Coaching Matters as Much as the Medication

Here is the reality most GLP-1 clinics will not tell you: studies show that people who stop GLP-1 medications without lifestyle changes regain roughly two-thirds of the weight they lost within a year. A 2022 study in Diabetes, Obesity and Metabolism found that participants regained 11.6% of their body weight within one year of stopping Semaglutide.

This is why we built our program differently. While the medication reduces your appetite and supports weight loss, our coaching program builds the nutrition framework and daily habits that sustain your results. You work one-on-one with a coach who helps you develop a sustainable relationship with food, so when the medication ends, the results stick.